The PLK4 inhibitor CFI-400945 demonstrated significant antitumor activity in SK-UT-1, SKN, and SK-LMS-1 and SK-UT-1 cell lines and uterine cancer xenografts.100. Here, PLK4 is linked to uterine cancer.